长春高新注射用GenSci139临床试验获批

Core Viewpoint - Changchun Gaoxin's subsidiary, Changchun Jinsai Pharmaceutical, has received approval from the National Medical Products Administration to conduct clinical trials for GenSci139 in patients with advanced solid tumors, which may enhance the company's business scope and product structure [1] Group 1 - The approval allows for the clinical trial of GenSci139, a drug intended for advanced solid tumor patients [1] - Successful progress in the clinical trial application is expected to broaden the company's business range and optimize its product structure [1] - The initiative aims to enrich and improve the strategic product line layout, thereby enhancing the company's core competitiveness [1]